![](https://canadanewsgroup.com/wp-content/uploads/2019/10/dna-test-tube-1024x683.jpg)
Inovio Pharmaceuticals Inc. (INO) had a good day on the market for Wednesday October 16 as shares jumped 12.05% to close at $2.51. About 998,395 shares traded hands on 3,306 trades for the day, compared with an average daily volume of n/a shares out of a total float of 99.03 million. After opening the trading day at $2.24, shares of Inovio Pharmaceuticals Inc. stayed within a range of $2.55 to $2.23.
With today’s gains, Inovio Pharmaceuticals Inc. now has a market cap of $248.56 million. Shares of Inovio Pharmaceuticals Inc. have been trading within a range of $5.68 and $1.92 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Inovio Pharmaceuticals Inc. is based out of Plymouth Meeting, PA and has some 281 employees. Its CEO is J. Joseph Kim.
Inovio Pharmaceuticals Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.